InflammX Therapeutics Announces Option Agreement with Bausch + Lomb
1. Bausch + Lomb may acquire InflammX Therapeutics through an option agreement. 2. This partnership aims to improve treatments for retinal diseases and macular degeneration. 3. InflammX's drug, Xiflam, targets inflammation in retinal conditions. 4. Bausch + Lomb seeks to accelerate development for unmet needs in ophthalmology. 5. This strategic move enhances Bausch + Lomb's retinal disease portfolio.